Cardiovascular Outcomes with Romosozumab Versus Alendronate in Osteoporosis: A Real-World Propensity-Matched Cohort Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #623; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "In this large real-world propensity-matched analysis, romosozumab initiation was not associated with increased cardiovascular events compared with alendronate, including among patients with prior cardiovascular disease and those who would have been excluded from the pivotal ARCH trial. The findings are consistent with prior real-world studies using PTH analogues as comparators. Pre-specified sensitivity analyses to quantify and adjust for differential healthcare surveillance and residual confounding by indication are ongoing and will be presented."
Clinical • Real-world • Real-world evidence • Cardiovascular • Ischemic stroke • Musculoskeletal Diseases • Myocardial Infarction • Orthopedics • Osteoporosis • Rheumatology
|
|
Husam El Sharu; Sarah Keller
|